Mirati Therapeutics, Inc. (MRTX) Given Consensus Recommendation of “Hold” by Brokerages
Mirati Therapeutics, Inc. (NASDAQ:MRTX) has been assigned an average rating of “Hold” from the eleven analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $13.17.
Several brokerages have recently issued reports on MRTX. Zacks Investment Research cut Mirati Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, October 5th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Mirati Therapeutics in a research note on Thursday, October 12th. SunTrust Banks, Inc. reiterated a “buy” rating and issued a $13.00 price objective on shares of Mirati Therapeutics in a research note on Thursday, October 12th. ValuEngine upgraded Mirati Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 15th. Finally, Cann began coverage on Mirati Therapeutics in a research note on Tuesday, September 19th. They issued an “outperform” rating for the company.
WARNING: This article was first reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/11/12/mirati-therapeutics-inc-mrtx-given-consensus-recommendation-of-hold-by-brokerages.html.
Mirati Therapeutics (NASDAQ MRTX) opened at $15.05 on Friday. Mirati Therapeutics has a 52 week low of $2.70 and a 52 week high of $16.50.
Mirati Therapeutics (NASDAQ:MRTX) last announced its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.16. equities research analysts forecast that Mirati Therapeutics will post -2.87 EPS for the current fiscal year.
In related news, SVP Jamie Christensen sold 7,499 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $14.00, for a total transaction of $104,986.00. Following the completion of the sale, the senior vice president now owns 10,169 shares in the company, valued at $142,366. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In the last 90 days, insiders have sold 12,269 shares of company stock valued at $170,226. 5.10% of the stock is owned by company insiders.
A number of hedge funds have recently bought and sold shares of the stock. Sabby Management LLC lifted its stake in Mirati Therapeutics by 2.1% during the second quarter. Sabby Management LLC now owns 255,100 shares of the biotechnology company’s stock worth $921,000 after purchasing an additional 5,365 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Mirati Therapeutics by 22.9% during the first quarter. Bank of New York Mellon Corp now owns 63,004 shares of the biotechnology company’s stock worth $328,000 after purchasing an additional 11,753 shares during the last quarter. Susquehanna International Group LLP lifted its stake in Mirati Therapeutics by 46.5% during the second quarter. Susquehanna International Group LLP now owns 50,509 shares of the biotechnology company’s stock worth $184,000 after purchasing an additional 16,030 shares during the last quarter. KCG Holdings Inc. purchased a new stake in Mirati Therapeutics during the first quarter worth approximately $106,000. Finally, Citadel Advisors LLC purchased a new stake in Mirati Therapeutics during the third quarter worth approximately $268,000. Hedge funds and other institutional investors own 60.26% of the company’s stock.
Mirati Therapeutics Company Profile
Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companys clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.
Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.